search
Back to results

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Primary Purpose

Malignant Neoplasm

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
PM8002
Sponsored by
Biotheus Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malignant Neoplasm

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures; Male or female aged 18 to 75 years; Patients with malignant tumor confirmed by histology or cytology; The toxicity of previous anti-tumor therapy has not been alleviated; Adequate organ function; ECOG score was 0-1; Expected survival >=12 weeks; According to RECIST 1.1 criteria, at least 1 measurable lesion that has not been previously treated locally. Exclusion Criteria: History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study; Evidence of major coagulopathy or other obvious risk of bleeding; Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy; Patients with uncontrolled brain metastases should be excluded from this clinical trial; Patients ever experienced other active malignant tumors within 5 years prior to the study treatment; Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Known history of alcohol abuse, psychotropic drug abuse or drug abuse; Syphilis antibody positive; Patients with active tuberculosis (TB) are excluded; Pregnant or lactating women; Other conditions lead to inappropriate to participate in this study as judged by the investigator.

Sites / Locations

  • Shanghai Orient HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PM8002

Arm Description

PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)

Outcomes

Primary Outcome Measures

Number of participants with DLTs
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (3weeks) of treatment.
Treatment related adverse events (TRAEs)
The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0
Objective response rate (ORR)
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

Secondary Outcome Measures

Disease control rate (DCR)
DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.
Duration of response (DoR)
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1). for subjects with no documented disease progression, the deadline is the data of the last examination.
Overall survival (OS)
OS is the time from the date of first dosing date to death due to any cause.
Progression-free survival (PFS)
Progression-free survival is defined as the time from the start of treatment with PM8002 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Anti-drug antibody (ADA)
To evaluate the incidence of ADA to PM8002.

Full Information

First Posted
May 30, 2023
Last Updated
June 25, 2023
Sponsor
Biotheus Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05918445
Brief Title
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Official Title
Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 9, 2021 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biotheus Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Neoplasm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
380 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PM8002
Arm Type
Experimental
Arm Description
PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)
Intervention Type
Drug
Intervention Name(s)
PM8002
Intervention Description
IV infusion
Primary Outcome Measure Information:
Title
Number of participants with DLTs
Description
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (3weeks) of treatment.
Time Frame
During the first three weeks of treatment with PM8002
Title
Treatment related adverse events (TRAEs)
Description
The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0
Time Frame
Up to 30 days after last treatment
Title
Objective response rate (ORR)
Description
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.
Time Frame
Up to approximately 2 years
Secondary Outcome Measure Information:
Title
Disease control rate (DCR)
Description
DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.
Time Frame
Up to approximately 2 years
Title
Duration of response (DoR)
Description
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1). for subjects with no documented disease progression, the deadline is the data of the last examination.
Time Frame
Up to approximately 2 years
Title
Overall survival (OS)
Description
OS is the time from the date of first dosing date to death due to any cause.
Time Frame
Up to approximately 2 years
Title
Progression-free survival (PFS)
Description
Progression-free survival is defined as the time from the start of treatment with PM8002 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Time Frame
Up to approximately 2 years
Title
Anti-drug antibody (ADA)
Description
To evaluate the incidence of ADA to PM8002.
Time Frame
Up to 30 days after last treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures; Male or female aged 18 to 75 years; Patients with malignant tumor confirmed by histology or cytology; The toxicity of previous anti-tumor therapy has not been alleviated; Adequate organ function; ECOG score was 0-1; Expected survival >=12 weeks; According to RECIST 1.1 criteria, at least 1 measurable lesion that has not been previously treated locally. Exclusion Criteria: History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study; Evidence of major coagulopathy or other obvious risk of bleeding; Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy; Patients with uncontrolled brain metastases should be excluded from this clinical trial; Patients ever experienced other active malignant tumors within 5 years prior to the study treatment; Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Known history of alcohol abuse, psychotropic drug abuse or drug abuse; Syphilis antibody positive; Patients with active tuberculosis (TB) are excluded; Pregnant or lactating women; Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
YE GUO
Phone
135 0167 8472
Email
pattrickguo@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
YE GUO
Organizational Affiliation
Shanghai Orient Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Orient Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
YE GUO
Phone
135 0167 8472
Email
pattrickguo@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.
IPD Sharing Time Frame
After the trial completed
IPD Sharing Access Criteria
NCI is committed to sharing data in accordance with NIH policy.

Learn more about this trial

PM8002 in the Treatment of Patients With Advanced Solid Tumors

We'll reach out to this number within 24 hrs